Anebulo Pharmaceuticals, Inc.
NASDAQ:ANEB
1.15 (USD) • At close April 28, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 1.221 | 1.315 | 0.468 | 0.748 | 1.063 | 1.27 | 1.417 | 1.089 | 1.87 | 1.224 | 1.118 | 0.915 | 0.213 | 0.715 | 1.807 | 0.273 | 0.17 | 0.02 | 0.15 |
| General & Administrative Expenses
| 1.368 | 1.097 | 0.873 | 0.916 | 1.698 | 1.273 | 1.077 | 1.775 | 1.943 | 1.388 | 1.207 | 0.964 | 0.858 | 0.84 | 0.678 | 0.279 | 0.155 | 0.232 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 1.368 | 1.097 | 0.873 | 0.916 | 1.698 | 1.273 | 1.077 | 1.775 | 1.943 | 1.388 | 1.207 | 0.964 | 0.858 | 0.84 | 0.678 | 0.279 | 0.155 | 0.232 | 0.023 |
| Other Expenses
| 0 | 0 | 0 | 0.002 | -0.001 | 0.008 | -0.001 | 0 | -0.014 | 0 | 0.001 | 0.003 | -0.002 | 0.002 | -0.001 | -0.004 | -0.004 | -0.004 | 0 |
| Operating Expenses
| 2.588 | 2.412 | 1.34 | 1.664 | 2.76 | 2.544 | 2.494 | 2.864 | 3.813 | 2.612 | 2.325 | 1.88 | 1.071 | 1.555 | 2.485 | 0.552 | 0.325 | 0.252 | 0.173 |
| Operating Income
| -2.588 | -2.412 | -1.34 | -1.664 | -2.76 | -2.544 | -2.494 | -2.864 | -3.813 | -2.612 | -2.325 | -1.88 | -1.071 | -1.555 | -2.485 | -0.552 | -0.325 | -0.252 | -0.173 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.125 | 0.211 | -0.01 | 0.011 | 0.043 | 0.063 | -0.001 | 0.066 | -0.014 | 0 | 0.003 | 0.003 | -0.002 | 0.002 | -26.627 | -0.004 | -0.004 | -0.004 | -0.001 |
| Income Before Tax
| -2.463 | -2.201 | -1.35 | -1.654 | -2.717 | -2.481 | -2.496 | -2.798 | -3.827 | -2.612 | -2.323 | -1.876 | -1.073 | -1.553 | -29.112 | -0.556 | -0.329 | -0.256 | -0.175 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 0 | -1.664 | -0.003 | -0.058 | 0.052 | 0 | 0.014 | -2.612 | -0.005 | -0.003 | 0.002 | -1.555 | -0.001 | -1.104 | -0.325 | -0.252 | 0 |
| Net Income
| -2.463 | -2.201 | -1.35 | -1.654 | -2.717 | -2.481 | -2.496 | -2.798 | -3.841 | -2.612 | -2.318 | -1.873 | -1.073 | -1.553 | -29.112 | -0.556 | -0.329 | -0.256 | -0.175 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.09 | -0.085 | -0.052 | -0.064 | -0.11 | -0.097 | -0.097 | -0.11 | -0.15 | -0.11 | -0.099 | -0.08 | -0.046 | -0.067 | -1.59 | -0.024 | -0.014 | -0.011 | -0.007 |
| EPS Diluted
| -0.09 | -0.085 | -0.052 | -0.064 | -0.11 | -0.097 | -0.097 | -0.11 | -0.15 | -0.11 | -0.099 | -0.08 | -0.046 | -0.067 | -1.59 | -0.024 | -0.014 | -0.011 | -0.007 |
| EBITDA
| -2.403 | -2.141 | -1.29 | -1.594 | -2.76 | -2.544 | -2.494 | -2.798 | -3.813 | 0 | 0.003 | -1.88 | -1.071 | -1.555 | -29.112 | -0.552 | -0.004 | -0.004 | -0.173 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |